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Neutralization of Junín virus by 
single domain antibodies targeted 
against the nucleoprotein
Florencia Linero1,2, Claudia Sepúlveda3, Ioanna Christopoulou1,2, Paco Hulpiau2,4, 
Luis Scolaro3 & Xavier Saelens  1,2
The syndrome viral haemorrhagic fever (VHF) designates a broad range of diseases that are caused by 
different viruses including members of the family Arenaviridae. Prophylaxis for Argentine Haemorrhagic 
Fever (AHF), caused by the arenavirus Junín (JUNV), has been achieved by the use of a live attenuated 
vaccine, named Candid#1. The standard treatment of AHF is transfusion of convalescent human 
plasma. Our aim was to develop an alternative and safer treatment for AHF based on the use of virus-
neutralizing single domain antibodies (VHHs). We describe the first reported VHHs directed against 
an arenavirus. These VHHs could neutralize Candid#1 by altering virion binding/fusion. Surprisingly, 
the neutralizing VHHs appeared to be specific for the viral nucleoprotein (N) that is not known to be 
involved in arenavirus entry. Candid#1 VHH-escape viruses had acquired a predicted N-glycosylation 
site in the surface glycoprotein GP1 that is present in highly pathogenic JUNV strains. Accordingly, the 
Candid#1-neutralizing VHHs could not neutralize pathogenic JUNV strains, but they could still bind 
to cells infected with a pathogenic strain or the escape mutant viruses. These results show that the 
attenuated strains of JUNV can be potently neutralized by nucleoprotein-specific VHHs.
Arenaviruses occur worldwide and can cause severe disease in humans. Members of the Arenaviridae family are 
enveloped viruses with a bi-partite RNA genome coding for four viral proteins. The viral nucleoprotein (N) and 
the glycoprotein precursor (GPC) are encoded by the small (S) genome segment, whereas the RNA-dependent 
RNA polymerase and the matrix protein (Z) are encoded by the large (L) segment. Both genome segments, S 
and L, use an ambisense coding strategy, with N and L oriented in negative sense and GPC and Z in positive 
sense relative to the genomic RNA, which is considered negative stranded. The Arenaviridae family is subdi-
vided into two genera: Mammarenavirus, members of which infect mammals, and Reptarenavirus, members of 
which infect snakes1–6. Rodents that are chronically infected with these viruses represent the natural reservoirs of 
Mammarenaviruses. However, some members of the Mammarenaviruses sporadically cause zoonotic infections 
in humans, which may lead to life-threatening viral haemorrhagic fever (VHF) disease7.
Mammarenaviruses are classified in two groups based on their genetic and geographical distribution: Old 
World (OW) viruses are found in Europe and Africa and New World (NW) viruses in the Americas. At pres-
ent, there are about 30 species of Mammarenaviruses described, 8 of which can cause severe VHFs in humans7. 
Humans can become infected with these viruses through direct contact with excreta of infected rodents or 
through inhalation of aerosols or dust particles that are contaminated with the virus. Person to person transmis-
sion is rare and has been reported for Lassa (LASV), Machupo (MACV) and Lujo (LUJV) viruses mostly during 
nosocomial care8,9.
VHFs caused by arenaviruses are acute diseases with considerable mortality rates. Symptoms are fever, 
malaise, headache, nausea, diarrhea, petechial hemorrhage of the soft tissues, lethargy, and irritability. However, 
in severe cases, patients can experience different degrees of bleeding, leukopenia, thrombocytopenia that are 
associated with a shock syndrome in the terminal stage10,11. The purine nucleoside analog ribavirin is the only 
off-label drug recommended for use in treating arenaviruses infections under emergency provisions12,13.
Argentine Hemorrhagic fever (AHF) is caused by the NW arenavirus JUNV, first isolated in Argentina from 
a human case in 195814,15. The wild rodents Calomys musculinus and Calomys laucha are the main reservoirs of 
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JUNV. The endemo-epidemic area of AHF has gradually expanded and currently comprises an area of 150.000 km2 
and the population at risk is approximately 5 million people16. The incubation period for AHF is estimated to be 
between 7 and 14 days17. The health of infected patients may improve after one or two weeks, but approximately 
one-third of untreated cases become severely ill with bleeding tendencies and/or neurological signs. Worsening of 
these symptoms is often fatal and 15–30% of AHF patients succumb to the infection. At present the transfusion of 
human immune plasma into patients with a clinical diagnosis of AHF is the only standard specific treatment for 
this disease. Such transfusion is effective only when applied during the first week of infection18. Moreover, devel-
opment of a late neurological syndrome in plasma treated patients, the scarcity of the immune plasma source and 
the risk of transfusion borne diseases are serious drawbacks of this treatment19.
Although prevention for AHF is possible through the use of a live attenuated vaccine, Candid#120,21, there is a 
safety risk associated with the administration of live attenuated virus vaccines to children, pregnant women and 
immunocompromised persons22,23. To circumvent these risks, monoclonal antibody-based therapies are under 
consideration. A recent report describes the development of humanized monoclonal antibodies that can prevent 
disease and death in the JUNV guinea pig model24. On this line, antibodies that bind antigens via a single protein 
domain were discovered in 1990 in some members of the Camelidae family and are under active investigation for 
immune therapies25. These so called heavy chain-only antibodies lack a light chain which means that their antigen 
recognition is confined to a single variable domain, named as VHH. These VHHs, also known as ‘Nanobodies®’, 
are currently explored for biotechnological and therapeutic applications because of their small size, simple pro-
duction and high affinity. We previously reported on the potential of recombinant VHHs to prevent and treat 
H5N1 influenza and human respiratory syncytial virus infection in experimental models26–29. In this work, we 
describe the selection and characterization of VHHs with potent in vitro antiviral activity against JUNV.
Results
Isolation and characterization of JUNV-specific single domain antibodies. Candid#1-specific 
VHHs were selected from a phage display library that was generated after immunization of an alpaca with puri-
fied UV-inactivated Candid#1 virions. VHH candidates were selected by biopanning, analysis of their sequence 
diversity and their capacity to neutralize Candid#1 (Supplementary Figs 1 and 2a). Three VHHs, named 1.2, 1.69 
and 2.96, were produced and purified from E. coli in mg amounts, and showed dose-dependent Candid#1 virus 
neutralizing activity with calculated IC50 concentrations in the low nM range (Fig. 1a). Additionally, VHH 2.3, 
which binds to Candid#1-infected cells but does not neutralize the virus, and VHH 2.80, which neither binds to 
nor neutralizes Candid#1 virus, were selected as controls (Fig. 1a). The predicted amino acid sequence of these 
selected VHHs revealed that the neutralizing VHHs 1.2, 1.69 and 2.96 have similar framework (FR) and comple-
mentarity determining regions (CDRs) (Supplementary Fig. 2b).
We next determined if the Candid#1 virus-binding VHHs could also bind to Candid#1 infected cells. VHH 
binding was assessed after fixation and permeabilization of Candid#1 infected Vero cell monolayers. All three 
neutralizing VHHs as well as the non-neutralizing VHH 2.3 bound to permeabilized, paraformaldehyde fixed 
infected cells whereas VHH 2.80 did not (Fig. 1b). As expected, JUNV N- and GPC-specific monoclonal anti-
bodies (mAbs) recognized viral antigens in fixed and permeabilized Candid#1-infected cell monolayers (Fig. 1b, 
right panel).
Next, we evaluated the capacity of the VHHs to bind intact infected cells, i.e. without prior permeabilization. 
By doing so, JUNV antigens that are membrane-exposed could be recognized by the VHHs. Thus, the VHHs were 
allowed to react with Candid#1-infected cells before fixation and the permeabilization step was omitted. Under 
these conditions the three neutralizing VHHs still bound to infected cells, while VHH 2.3 (and VHH 2.80) did 
not (Fig. 1c). These results suggest that the neutralizing VHHs 1.2, 1.69 and 2.96 recognize a virus-associated sur-
face exposed antigen on infected cells. As expected, anti-GPC mAbs specifically bound to infected cells that were 
not permeabilized in agreement with the surface-exposed nature of GPC (Fig. 1c, right panel). On the contrary, 
N-specific mAbs failed to bind under these conditions, in accordance with the expected cytoplasmic expression 
of the viral N (Fig. 1c, right panel).
To obtain more insight into the neutralization process of the Candid#1-specific VHHs, we performed exper-
iments in which the VHHs were added before or after virion attachment to Vero cells. No significant antiviral 
effect was observed when VHHs or control N- or GPC-specific mAbs were added to the cells before infection and 
subsequently washed away (Fig. 2a, white bars, cell pretreatment). This indicates that a host cell factor (e.g. trans-
ferrin receptor) involved in Candid#1 attachment or entry30 was not targeted by these antibodies. In contrast, the 
three neutralizing VHHs, like the GPC-specific mAbs, reduced infection dose-dependently when they were incu-
bated together with the virus before attachment (Fig. 2a, gray bars, pre-attachment). Remarkably, incubation after 
virus attachment also resulted in inhibition of virus replication suggesting that the antiviral effect of the VHHs 
as well as GPC-specific antibodies is also operative after viral adsorption (Fig. 2a, black bars, post-attachment). 
The non-neutralizing VHHs 2.80 and 2.3, as well as the N-specific mAbs failed to suppress Candid#1 replication 
in any of the conditions evaluated (Fig. 2a). We can thus conclude that the neutralizing VHHs 1.2, 1.69 and 2.96 
prevent infection by interfering with virion adsorption and/or uncoating, in a similar fashion as GPC-specific 
mAbs do.
Attachment of JUNV to its receptor, the transferrin 1 receptor, is followed by clathrin-mediated endocyto-
sis, virion delivery into endosomes and a pH-dependent membrane fusion mediated by GPC30,31. To evaluate 
if the neutralizing VHHs could prevent membrane fusion, we performed a cell-cell fusion assays in Candid#1 
infected Vero cells. Cells were infected with Candid#1 and 48 h after infection VHHs, N- or GPC-specific mAbs 
were added to the cells. Subsequently, the cells were kept at neutral pH or exposed to pH 5.0 for 3 h to trig-
ger GPC-mediated syncytium formation. Finally, the pH of the medium was neutralized for 1 h and the cells 
were fixed and stained. The presence of multinucleated cells was analyzed by bright field microscopy (Fig. 2b). 
Syncytium formation in untreated Candid#1 infected cells was only observed after exposure of cells to pH 5 
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(Fig. 2b). As expected, GPC-specific mAbs but not N-specific mAbs, prevented pH-induced syncytium formation 
(Fig. 2c). All three neutralizing VHHs also prevented syncytium formation in a dose-dependent manner, while 
no effect was observed for VHH 2.3 and 2.80 (Fig. 2d). In summary, these results indicate that the neutralizing 
activity of VHHs 1.2, 1.69 and 2.96 correlates with their capacity to interfere with Candid#1-mediated syncytium 
formation.
Candid#1-neutralizing VHHs are specific for the viral nucleoprotein. To identify the viral antigen 
that is targeted by the VHHs, we performed co-localization assays with N- or GPC-specific mAbs in infected 
cells. In a first set of experiments, Vero cells were infected with Candid#1 virus, fixed, permeabilized and then 
incubated with the mAbs and the VHHs. GPC- and N-specific mAbs bound to the infected cells in a typical 
perinuclear dotted pattern for GPC and a granular cytoplasmic fluorescence pattern for N (Fig. 3a,b)32,33. Under 
these conditions, fluorescent signals derived from the GPC-specific mAbs and the neutralizing VHHs showed 
some co-localization with calculated Pearson’s correlation coefficient values below 0.2 (Fig. 3a,d). By contrast, 
fluorescent signals revealed by the neutralizing VHHs 1.2, 1.69 and 2.96, the non-neutralizing VHH 2.3 and the 
Figure 1. VHHs 1.2, 1.69 and 2.96 neutralize Candid#1 virions and bind to Candid#1 infected cells. (a) The 
50% inhibitory concentration (IC50) of the purified VHHs was determined by infection of Vero cells with 50 
PFU of Candid#1 that had been previously incubated with serial dilutions of the indicated purified His-tagged 
VHHs. At 3 days p.i. virus plaques were visualized and counted by immunostaining. Virus yield in the Y-axis 
is expressed as the percentage of plaques relative to the untreated control. The IC50 value (right) of the VHHs 
was calculated from three independent experiments (performed in duplicate) and error bars represent the SD 
of the mean. (b) The binding of the VHHs to infected cells was evaluated by ELISA in Vero cells infected with 
50 PFU of Candid#1. At 72 h p.i, cells were fixed, permeabilized and afterwards incubated with serial dilutions 
of the indicated VHHs (left) or JUNV mAbs (right). (c) Alternatively, Candid#1 infected Vero cells were first 
incubated with serial dilutions of VHHs or JUNV mAbs and afterwards fixed, without prior permeabilization. 
VHHs binding curves are depicted in the left panels and N- and GPC-specific mAbs binding curves on the 
right. Results show the mean of three independent experiments and error bars represent the SD of the mean.
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Figure 2. VHHs neutralize Candid#1 at a step following attachment. (a) Panels represent the results of the 
treatment with the indicated VHH or mAbs. The timing of the infection relative to the other treatments is 
schematically shown in the bottom right in which the transferrin receptor (Tfr-R), JUNV virions and the VHH, 
are schematized. For the cell pre-treatment assay, Vero cells were incubated with serial dilutions of VHHs for 1 h 
at 37 °C, then chilled on ice for 15 min and then incubated with 50 PFU of Candid#1 virus 1 h at 4 °C to allow 
virus attachment. After attachment, the cells were washed with cold medium and then shifted to 37 °C (white 
bars). For the pre-attachment assay 50 PFU of Candid#1 virus were mixed with serial dilutions of VHHs and 
incubated at 37 °C for 1 h prior to inoculation of Vero cells (gray bars). For the post-attachment assay Candid#1 
virus virions were added to pre-chilled Vero cells, incubated for 1 h at 4 °C and afterwards incubated with 
1/10 serial dilutions of VHHs during 1 h at 37 °C (black bars). At 3 days p.i. the extent of viral replication was 
quantified by ELISA. (b) Vero cells were mock infected or infected with Candid#1 at an MOI of 0.05 PFU/cell. 
At 48 h p.i. monolayers were mock treated or incubated for 2 h with serial dilutions of VHHs or JUNV-specific 
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N-specific mAbs overlapped almost completely, as supported by the deduced Pearson’s correlation coefficient 
values, which ranged from 0.8 to 0.92 (Fig. 3b,d). Mock infected cells did not show any positive signal when 
incubated with VHHs and N-specific mAbs (Fig. 3c). These findings suggest that the VHHs bind to N or to a viral 
epitope that is very close to N.
Next, immuno-stainings of Candid#1-infected cells were repeated but now VHHs and the GPC- or N-specific 
mAbs were allowed to bind to the cells before fixation (i.e. the permeabilization step was omitted). As expected, 
under these conditions the GPC-specific mAbs bound to infected cells, indicating that they could recognize viral 
antigens exposed on the cell surface (Fig. 4a). By contrast, the N-specific mAbs failed to bind to infected cells, 
which is in line with the assumed cytoplasmic localization expected for N (Fig. 4b). Surprisingly, we found that 
VHHs 1.2, 1.69, 2.96 and 2.3 bound specifically to non-permeabilized Candid#1-infected cells (Fig. 4a,b), while 
no signal was detected in mock infected cells (Fig. 4c). Furthermore, the three neutralizing VHHs, as well as VHH 
2.3, partially co-distributed with the GPC-specific mAbs under these conditions, with a Pearson´s coefficient 
value of approximately 0.4 (Fig. 4a,d). Combined with the immuno-fluorescence results obtained from permeabi-
lized infected cells, these data suggest that the Candid#1-specific VHHs 1.2, 1.69, 2.96 and 2.3 are directed against 
a viral antigen that is accessible on the surface of infected cells.
Next, we evaluated the binding of the neutralizing VHHs to N-expressing cells. An expression plasmid for 
N derived from Candid#1 or XJCl3 virus was transiently transfected in Vero cells. Afterwards the cells were 
fixed, permeabilized and further probed with N-specific mAbs and the VHHs. This revealed that fluorescent 
signals detected after staining with N-specific mAbs and with VHHs 1.2, 1.69, 1.96 and 2.3 almost completely 
overlapped (Fig. 5a,b). To note, without prior permeabilization, no signal was observed for the N-specific mAbs 
in N-transfected cells (Supplementary Fig. 3a). None of the VHHs could stain cells that had been transfected 
with a GPC expression vector that either contained GPC from Candid#1 or XJ strains (Supplementary Fig. 3b). 
Collectively these results point out that the viral target of the neutralizing VHHs is a part of the N protein that is 
exposed on the cell membrane. Notably, cell surface accessibility of this part of the N protein occurs in the context 
of a viral infection, but not when N is expressed alone.
Selection of in vitro neutralization escape viruses followed by nucleotide sequence analysis is a conventional 
method to study the potential binding site of a virus neutralizing antibody or VHH26. Therefore, we passaged 
Candid#1 virus in the presence of VHH 1.2, 1.69 or 2.96 and the resulting escape viruses were characterized. 
Candid#1 virus was also passaged in the presence of non-neutralizing control VHHs 2.3, VHH 2.80 and an 
irrelevant VHH directed against an influenza A virus protein. No viruses that had acquired resistance against 
VHH 1.2, 1.69 or 2.96 were observed when Candid#1 virus was passaged in the presence of the control VHHs 
(Supplementary Fig. 4). However, Candid#1 escape viruses obtained with any of the three neutralizing VHHs 
were also resistant to neutralization by the two other VHHs but remained susceptible to neutralization by 
GPC-specific mAbs (Fig. 6a). Surprisingly, no mutation was detected in either the N (the likely target of the neu-
tralizing VHHs based on the immune-fluorescence analysis) or Z genes of these VHH escape viruses. Instead, we 
found an alanine to threonine amino acid substitution at position 168 in the predicted GPC sequence (Fig. 6b). 
To evaluate if the loss of neutralization was due to the inability of the VHHs to bind to the escape mutant viruses, 
immunofluorescence assays were performed. In line with the unaltered N sequence, all three neutralizing VHHs 
could still bind to cells that had been infected with the escape mutant viruses. N-specific mAbs and the VHHs 
co-localized when cells had been fixed and permeabilized prior to immune-staining (Fig. 7a,c). VHHs 1.2, 1.69 
and 2.96 also still partially co-localized with GPC when cells were immuno-stained prior to fixation (Fig. 7b,c). 
These results indicate that, although resistant to the VHH neutralization, the N protein of VHH escape mutants 
displays the same antigenicity as the parental Candid#1 virus and that the N protein could be readily detected on 
the surface of non-permeabilized cells that had been infected with the escape viruses.
Candid#1-neutralizing VHHs do not neutralize pathogenic JUNV. Candid#1 is an attenuated JUNV 
strain that was derived from the pathogenic XJ strain by serial passaging in guinea pigs, mouse brain, and cul-
tured fetal rhesus monkey lung cells34. The immunogenicity and protective efficacy of Candid#1 used as a live 
attenuated vaccine has been tested in animal models and in clinical trials35–37. The surmised mechanism of pro-
tection of Candid#1 vaccine-mediated immunity is the suppression of virus entry by neutralizing antibodies that 
can be induced by this vaccine. Interestingly, the A168T variant obtained by selection of in vitro Candid#1 VHH 
neutralization escape viruses recreates the N-linked glycosylation site that is found in the pathogenic XJ isolate 
of JUNV that was lost in the attenuation process that resulted in Candid#120,38,39 (Fig. 8a). Based on this, it was 
expected that Candid#1 neutralizing VHHs would fail to inhibit the pathogenic XJ strain of JUNV. A modified 
neutralization assay, in which virus replication was measured by ELISA, showed that VHHs 1.2, 1.69 and 2.96 
neutralized the attenuated XJCl3 and Candid#1 viruses equally well (Fig. 8b). However, in vitro replication of the 
pathogenic XJ strain was not prevented by any of the three Candid#1-neutralizing VHHs, not even when these 
were applied at up to 4 µM concentration (Fig. 8b,c). Similar results were obtained when a plaque assay was used 
as a readout (Fig. 8d). To note, the hyperimmune plasma of the Candid#1 immunized alpaca (JUNV-alpaca) 
could inhibit XJ replication in vitro (Fig. 8b) indicating the presence of neutralizing antibodies, conventional 
or heavy chain-only antibodies, other than the VHHs explored in this work, which were obtained by probing 
mAbs. Afterwards, syncytium formation was induced by incubation in acidic media (pH = 5) and the presence 
of multinucleated cells was evaluated by Giemsa staining (bright field pictures). (c) Syncytium formation 
in presence of serial dilutions of GPC and N- specific mAbs. (d) Syncytium formation in presence of serial 
dilutions of VHHs. Representative results from three independent experiments are shown. The scale bar in the 
bright field images represents 100 µm.
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Figure 3. VHHs 1.2, 1.69, 2.96 and 2.3 colocalize with JUNV N-specific Mabs in fixed and permeabilized 
Candid#1 infected cells. Vero cells were mock infected or infected with 150 PFU of Candid#1. At 48 h p.i. 
cells were fixed, permeabilized and further incubated with 10 µM of VHHs followed by incubation with GPC- 
(a) or N-specific mAbs (b). Afterwards, monolayers were incubated with an anti-His antibody and finally 
incubated with the corresponding secondary antibodies. Anti-His antibody without the VHH was included as 
a negative control (-VHH) and incubation with a VHH against an influenza epitope (VHH Flu) was used as 
control as well. (c) In addition, immune-staining was performed in mock-infected cells with VHHs followed 
by incubation with N-specific mAbs. (d) Colocalization of the VHH-specific fluorescent signal with that of the 
GPC- an N-specific mAbs was determined in 50 cells that showed a positive signal with GPC- or N-specific 
mAbs. The Pearson’s correlation coefficient (P) was calculated using the Coste’s algorithm provided in the 
Volocity software package. The scale bar represents 25 µm.
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Figure 4. VHHs 1.2, 1.69, 2.96 and 2.3 do not colocalize with JUNV N- or GPC-specific Mabs in fixed non-
permeabilized Candid#1 infected cells. Vero cells were mock infected or infected with 150 PFU of Candid#1. 
At 48 h p.i. cells were first incubated with 10 µM of VHHs followed by incubation with a 1:600 dilution of 
GPC- (a) or N-specific mAbs (b) in a CO2 incubator. Afterwards the cells were fixed with 2% PFA (without 
a permeabilization step) and further incubated with an anti-His antibody followed by incubation with 
the respective secondary antibodies. Anti-His antibody without the presence of VHH was used (−VHH), 
incubation with a VHH against Flu (VHH Flu) and mock infected cells were used as negative controls. (c) 
Immune-staining was performed in mock-infected cells with VHHs followed by incubation with N-specific 
mAbs. (d) Colocalization of the VHH-specific fluorescent signal with that of the GPC- an N-specific mAbs was 
determined in 50 cells that showed a positive signal with GPC- or N-specific mAbs. The Pearson’s correlation 
coefficient (P) was calculated using the Coste’s algorithm provided in the Volocity software package. The scale 
bar represents 25 µm.
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Figure 5. VHHs 1.2, 1.69, 2.96 and 2.3 recognize N derived from Candid# and XJCl3 strains. (a) Vero cells 
at 60% confluence were transfected with 200 ng of expression plasmids coding for N from Candid# (left) or 
XJCl3 (right) strains. At 48 h post-transfection, the cells were fixed, permeabilized and further incubated with 
10 µM of VHHs followed by incubation with N-specific mAbs. Afterwards, cells were incubated with an anti-
His antibody and finally incubated with the respective secondary antibodies. Immuno-staining without VHH 
(−VHH), without N-specific mAb (−N), with a VHH against Flu (VHH Flu) and with GPC-specific mAbs 
(GPC) were included as controls. Pictures are representative of 3 independent experiments. (b) Colocalization 
of the fluorescent signal derived from immuno-staining with the VHHs was determined in 30 cells that showed 
a positive signal with N-specific mAbs. The Pearson’s correlation coefficient (P) was calculated using the Coste’s 
algorithm provided in the Volocity software package. The scale bar represents 25 µm.
www.nature.com/scientificreports/
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a phage display library derived from the immunized alpaca. Despite the lack of inhibition, the Candid#1 neu-
tralizing VHHs did bind to XJ-infected cells as evidenced by immunofluorescence microscopy (Fig. 8e). These 
results are in agreement with the observation that the Candid#1 neutralizing VHHs could still specifically bind 
to cells that had been infected with the escape viruses. Therefore, although amino acid residue 168 in the GPC 
sequence influences the neutralizing activity of the VHHs 1.2, 1.69 and 2.96 against the JUNV strains, the fact that 
an XJ-associated determinant is recognized by these VHHs in XJ-infected cells points out that another protein, 
presumably N, is the target of these Candid#1-neutralizing VHHs.
Discussion
The aim of this project was to obtain single domain antibodies against JUNV with the purpose to explore this 
technology as a potential therapeutic option for AHF. The main conclusion of our work, however, is that VHHs 
that are most likely directed against the N protein of JUNV can neutralize the Candid# virus. These VHHs were 
able to target N at the plasma membrane of infected cells and prevent viral replication by disturbing virus entry. 
This is unexpected, because there is no evidence reported yet that the N protein of Arenaviruses is involved in 
these early steps of the virus life cycle. The three neutralizing VHHs were obtained after immunization of an 
alpaca with UV-inactivated Candid#1, an attenuated strain of JUNV. These VHHs, named 1.2, 1.69 and 2.96, 
showed binding activity for both attenuated and pathogenic JUNV strains, but only exhibited a potent in vitro 
inhibitory activity against the attenuated strains Candid#1 and XJCl3. Besides, a membrane-binding pattern 
observed in Candid#1 infected cells, the three VHHs did not or at best partially co-localize with GPC-specific 
mAbs and failed to bind to GPC-expressing cells. In addition, the three neutralizing VHHs bound to perme-
abilized transfected cells that expressed N from Candid#1 or XJCl3 and colocalized with N-specific mAbs in 
Candid#1 infected cells. Unexpectedly in vitro selected Candid#1 mutant viruses that escaped the neutralizing 
activity of VHHs 1.2, 1.69 and 2.96 had wild type N and Z proteins, and an A168T mutation in the GP1 domain 
of GPC. GPC is posttranslationally cleaved into GP1, GP2 and a stable signal peptide (SSP) which remains 
Figure 6. VHHs 1.2, 1.69 and 2.96 Candid#1 escape viruses carry a point mutation in GPC. In vitro escape 
mutants were generated by 3 passages of Candid#1 in the presence of 1000-fold the IC50 of the VHHs. (a) After 
the passages, escape viruses were evaluated in a neutralization assay by using 50 PFU of the respective escape 
viruses and 1 µM of VHHs or GPC- and N-specific mAbs. Neutralization was determined by ELISA. Results are 
expressed as percentage relative to the untreated control. The mean of three independent experiments (n = 3) 
is shown, where the error bars represent the standard deviation of the mean (SD). (b) Multiple alignment of the 
predicted amino acid sequence of part of the GPC from the escape mutants obtained under selective pressure 
with the neutralizing VHHs is shown from residues 141 to 220. The black triangle indicates the altered position 
in GPC of the escape viruses.
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Figure 7. VHHs 1.2, 1.69 and 2.96 colocalize with N of the VHHs escape mutant viruses in infected cells. Vero 
cells were mock infected or infected with 150 PFU of VHHs escape mutant viruses obtained after selection with 
VHH1.2, VHH 1.69 or VHH 2.96, respectively. At 48 h p.i. the cells were processed for IFA either before fixation 
and without permeabilization (a) or after fixation followed by permeabilization (b). Monolayers were incubated 
with 10 µM of the indicated VHHs followed by incubation with GPC- or N-specific mAbs. Afterwards, the 
cells were incubated with an anti-His antibody and finally incubated with the respective secondary antibodies. 
Control staining in the absence of VHH (−VHH) were included (lower panels). Representative results are 
shown for the VHH 1.69 escape mutant virus. Similar results were obtained for the VHH 1.2 and VHH 2.96 
escape mutants (pictures not shown). (c) Colocalization of the fluorescent signal derived from immuno-staining 
with the VHHs was determined in 50 cells that showed a positive signal with GPC- or N-specific mAbs for each 
condition. The Pearson’s correlation coefficient (P) was calculated using the Coste’s algorithm provided in the 
Volocity software package. The scale bar represents 25 µm.
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Figure 8. VHHs 1.2, 1.69 and 2.96 bind to cells infected with the pathogenic strain XJ but do not neutralize 
this virus. (a) Amino acid sequence alignment of part of GPC from JUNV XJ, XJCI3 and Candid#1 (adapted 
from Droniou-Bonzom et al.39). The last line of the alignment represents part of the sequence of GPC from 
the VHHs escape mutants that were obtained during this work. The mutation at position 168 is shown in red. 
(b) XJ, XJCl3 or Candid#1 (50 PFU) were incubated with 1 µM of each VHH and then added to Vero cells that 
had been seeded in 96 well-plates. The pre-immune and Candid#1-immune alpaca serum were evaluated at 
1/50 dilution. At 72 h p.i., cells were fixed and virus infection was quantified by ELISA. The scheme at the top 
represents the path to attenuation of the highly pathogenic XJ strain, over XJCI3 to Candid#1. (c) 50 PFU of XJ 
strain were incubated with different concentration of the VHHs or with 1/50 XJ-immune guinea pig serum and 
then added to Vero cells seeded in 96-well plates. At 3 days p.i. cell monolayers were fixed and virus infection 
was quantified by ELISA. (d) XJ strain virus (100 PFU) was incubated with different concentrations of VHHs 
or with 1/50 XJ-immune guinea pig serum (anti-XJ) and then added to Vero cells seeded in 24 well-plates. At 7 
days p.i. the cell monolayers were fixed and viral plaques were determined by counter staining of the remaining 
cells with crystal violet. Results in (c) and (d) represent the mean of three independent experiments (n = 3) and 
error bars represent the standard deviation of the mean. (e) Vero cells growth in coverslips at 90% confluence 
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associated with the processed protein to form the mature, trimeric GPC. GP1 is the virion attachment protein 
and is associated with the membrane anchored GP2 which in turn interacts with SSP. In line with an unaltered 
N sequence, the three VHHs could still bind to cells that had been infected with the escape variant viruses. Our 
findings thus show that VHHs that bind to JUNV N can prevent Candid#1 virus entry and syncytium formation 
(membrane fusion), i.e. 2 processes that depend on GPC.
These striking properties of these JUNV N-specific VHHs may be ascribed to their particular structure. VHHs 
consist of a single variable antibody domain with a molecular weight of 12–15 kDa. Their small size, ease of pro-
duction, high solubility, compact conformation, low tendency to form aggregates and high tissue penetration 
capacity make VHHs promising therapeutics40,41. Indeed, several Nanobodies® are being evaluated in clinical 
trials. One of the most advanced is ALX-0171 developed by Ablynx Inc. to treat disease caused by human res-
piratory syncytial virus (RSV) infection. This trivalent monospecific VHH targets the RSV fusion protein (F) and 
its use was associated with a reduction of viral replication and symptoms in RSV-infected children42. We have 
recently reported on two potent RSV neutralizing VHHs that selectively bind to the prefusion form of RSV F29. 
Furthermore, repeated daily oral administration of a VHH against rotavirus, delivered as part of a crude yeast 
extract, to male children with acute watery diarrhea was associated with a modest therapeutic effect43,44.
In vitro, antibodies can inhibit viral replication by different mechanisms: the induction of virion aggregation, 
destabilization of the virion structure, inhibition of virion attachment to target cells, inhibition of the fusion of 
the virion lipid membrane with the host cell membrane, prevention of viral genome release, inhibition of a func-
tion of the virion core through a signal transduced by an antibody, intracellular effects exerted by transcytosing 
IgA, and binding to nascent virions that blocks their budding or release from the cell surface45. The neutralizing 
VHHs described here prevent virion entry. Unexpectedly, neutralizing JUNV VHHs likely target the Candid#1N 
protein, which hitherto was not known to be involved in JUNV entry. Membrane fusion requires the participa-
tion of the viral glycoprotein processing products, GP2 and the cleaved SSP46,47. The neutralizing VHHs bound 
to the surface of intact (non-permeabilized) Candid#1-infected cells, which indicates that N is accessible on the 
cell surface. The fact that N, assumed to be an internal viral antigen, may be exposed on the cell surface although 
it lacks any conventional transmembrane domain or canonical targeting motif, may not be totally unexpected. 
Membrane expression of proteins that lack those motifs have been reported48,49. Moreover, a pioneering study of 
the prototype Arenaviridae family member lymphocytic choriomeningitis virus (LCMV) reported on the acces-
sibility of N on the plasma membrane surface of LCMV-infected cells and on the surface of the virions for LCMV 
N-specific mAbs50,51. Although, these LCMV N-specific mAbs and the JUNV N-specific mAbs used in our study 
completely lack virus neutralization activity in vitro, the N-specific VHHs described here potently neutralize 
the Candid#1 virus. Further studies showed that N-mAbs that recognize epitopes of LCMV NP present on the 
cell surface of LCMV infected cells, are able to enhance in vivo virus clearance52. Based on our results, during 
JUNV infection N epitopes also become exposed on the membrane of infected cells, and become accessible for 
N-specific VHHs but not for the conventional monoclonal antibodies used in our study.
Our findings are somewhat reminiscent of earlier reports on VHHs that are directed against the VP6 inner 
capsid protein of rotavirus that yet have neutralizing activity. Conventional antibodies against VP6 do not or very 
poorly neutralize rotavirus in vitro, presumably because the antigen is poorly accessible. However, VP6-specific 
VHHs can neutralize rotavirus possibly because they can access epitopes on VP6 that are important for viral 
entry: VP6 is involved in rotavirus entry by binding to the host factor hsp7053,54. However, Candid#1N is 
not known to be involved in virus entry. We note that binding of VHHs 1.2, 1.69 and 2.96 to the surface of 
non-permeabilized cells was only observed with Candid#1-infected cells but not in cells that overexpressed N. 
This indicates that N may require an interaction with other viral proteins to reach the plasma membrane. Again 
some parallel with LCMV may be noted since it has been proposed that a phosphorylated form of the nucleopro-
tein of this virus interacts with the glycoprotein at the level of the plasma membrane of infected cells and as such 
N becomes exposed on the cell surface50,51. One interesting point to note, that supports the idea of an interaction 
of Candid#1N with GP1, is the fact that viral escape mutants obtained by selective pressure exerted by the neu-
tralizing VHHs showed one amino acid substitution (A168T) in GP1. However, cells infected with these escape 
viruses were still recognized by the neutralizing VHHs, indicating that exposure of N at the membrane surface 
was not affected by the A168T mutation in GP1. The substitution of threonine at position 168 to alanine results in 
loss of an N-glycosylation site in GP1 that has been acquired during the attenuation linage of JUNV that resulted 
in Candid#120. Although this change was initially reported to be unrelated to Candid#1 attenuation38,55, a recent 
study related the absence of this N-linked glycosylation motif in GP1 of Candid#1 with an altered processing and 
reduced surface expression of GP1 in infected cells56. A limitation of our study is that we could not yet demon-
strate a direct interaction between N and the neutralizing VHHs 1.2, 1.69 and 2.96. Indeed, we have used VHHs 
1.2, 1.69 and 2.3 to try to immuno-precipitate N from Candid#1 virus infected cells. However, only VHH 2.3, 
which is non-neutralizing, was capable of immuno-precipitating N from infected cells (Supplementary Fig. 5). 
Possibly, the detergent lysis and washing conditions that were used are detrimental for the epitope in JUNV N that 
is recognized by the neutralizing VHHs described here.
We speculate that neutralization exerted by the JUNV VHHs could be due to a perturbation of the spatial 
structure of the glycoprotein on the membrane caused by the binding of the VHHs to N (which would be in close 
were infected with 150 PFU of Candid#1, XJCl3 or XJ strains. At 48 h p.i. the cells were fixed, permeabilized and 
afterwards incubated with 10 µM of the indicated VHHs or a mix of N- and GPC-specific mAbs. Monolayers 
were further incubated with an anti-His antibody to detect the VHHs and finally the corresponding secondary 
antibodies were added. The coverslips were mounted and visualized by immunofluorescence. Scale bar 
represents 100 µm.
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proximity to the glycoprotein). It is possible that GP1 from Candid#1 could also require a receptor shift upon 
acidification in order to promote virus membrane fusion as has been reported for LCMV57. Such a receptor shift 
could perhaps be hindered by VHHs that bind to N. In conclusion, N may be a target of JUNV neutralizing single 
domain antibodies.
Methods
Ethics statement. Immunizations and handling of the alpaca were by an accredited veterinarian according 
to the local guidelines for animal care and handling, and were authorized by ethical committee for animal exper-
iments of the Vrije Universiteit Brussel (permit No. 13-601-1).
Virus preparations. A purified stock of Candid#1 strain (kindly provided by Dr. Victor Romanowski, 
Facultad de Ciencias Exactas, La Plata, Argentina) either concentrated and non-concentrated was prepared as 
previously described58. For alpaca immunization, inactivation of the stock was done by exposing infectious virus 
to a 30 W UV light at a distance of 10 cm for 8 min.
XJ and XJCl3 virus stocks were routinely maintained at the Laboratorio de Virología, FCEyN, Universidad 
de Buenos Aires and originally supplied by the Cátedra de Microbiología, Facultad de Medicina, Universidad de 
Buenos Aires).
VHH isolation and production. An alpaca (Vicugna pacos) was immunized by six weekly intramuscular 
injections with 50 µg of purified and concentrated UV-inactivated Candid#1 strain of JUNV (corresponding to 
an original infectivity of 1.107 PFU) in the presence of Gerbu LQ#3000 adjuvant. The immune plasma collected 
after immunization was tested to evaluate its neutralizing activity against Candid# 1 (Supplementary Fig. 6). 
Afterwards, a VHH phage display library from the mononuclear cells of the immunized animal was generated in 
the phagemid vector pHEN4-HA59. The resulting phage display library was enriched for Candid#1-binding VHH 
candidates by two consecutive rounds of panning on immobilized UV-inactivated Candid#1 virions. Ninety-five 
random clones were selected after the first and 96 random clones after the second panning round. Periplasmic 
extracts (PE) were prepared from each of these clones by using lysis-phosphate buffer (50 mM Na2PO4H; 300 mM 
NaCl). The resulting PE extracts were evaluated by PE-ELISA using coated inactivated Candid#1 virions as 
target. Thirty Candid#1-binding candidates were obtained after the first and second panning round combined 
(Supplementary Fig. 1a).The PE extracts were then evaluated in a Candid#1 neutralization assay with a criteria 
to define the potential neutralizing candidates as those PEs with a neutralization activity higher than 50% com-
pared with a PE obtained from control bacteria. Based on these criteria we selected 9 VHH candidates from 
the first and two from the second panning round (Supplementary Fig. 1b). The nucleotide sequence of thirty 
Candid#1-binding candidates was determined and clustered phylogenetically using a Maximum Likelihood 
method (Supplementary Fig. 2a).
The VHH coding sequences that were determined based on the PE-ELISA selection were transferred into 
the pHEN6-6x His tag expression plasmid. Briefly, VHHs coding sequence from pHEN4-HA were ampli-
fied by PCR with the Primer A6E 5′GATGTGCAGCTGCAGGAGTCTGGRGGAGG 3′ and Primer 38 
5′GGACTAGTGCGGCCGCTGGAGACGGTGACCTGGGT 3′containing a PstI and BstEII restriction site 
(underlined), respectively. The PCR products were then digested with the respective enzymes and sub-cloned in 
the pHEN6-6x His tag vector in frame with a C-terminal His-6 tag.
Following transformation of E. coli cells with the pHEN6-VHH plasmids, single colonies were used to inoc-
ulate 5 ml LB pre-cultures. After overnight incubation, 1 ml of pre-culture was used to inoculate 300 ml LB and 
further induced with 1 mM IPTG. PE were prepared by using lysis-phosphate buffer and the VHHs were purified 
by Ni-NTA chromatography.
Plasmids expressing viral proteins. To construct plasmids expressing the viral proteins, total RNA 
was extracted from Candid#1 or XJCl3 infected cells and the cDNA was further synthesized by using the arena 
primer (ARS1) as described elsewhere58. The Junin mammarenavirus strain XJCl3 nucleoprotein and gly-
coprotein precursor gene sequences have been deposited in Genbank under accession numbers MG189700.1 
and MG189701.1, respectively. The coding sequences for the viral proteins N and GPC, were PCR amplified 
using primers compatible with the Gateway recombination system. The following primers were used: Gate 
N Cand#1 fw 5′GGGGACAACTTTGTACAAAAAAGTTGGCATGGCACACTCCAAAGAGG-3′, Gate N 
Cand#1 rv 5′-GGGGACAACTTTGTACAAGAAAGTTGGCAACAGTGCATAGGCTGCCTTCG-3′, Gate 
GPC fw 5′-GGGGACAACTTTGTACAAAAAAGTTGGCATGGGGCAGTTCATTAGC-3′, Gate GPC rv 
5′-GGGGACAACTTTGTACAAGAAAGTTGGCAATTAGCATTTCAGAAATTAAGA AGTC-3′. The plasmid 
pSEL1 + 2L was used as the destination vector.
Transfection was performed in Vero cells by using Fugene following the manufacturer´s instructions. Briefly, 
20,000 cells were seeded in each well of a 96-well plate, and 200 ng of plasmid was incubated with 0,3 µl of Fugene 
in Optimem in a final volume of 10 µl during 15 min. Afterwards the mix was added to the cells that had been 
refreshed with 100 μl of Optimem without serum and incubated at 37 °C in a CO2 (5%) incubator. At 48 h post 
transfection the cells were processed according to the respective experiment.
Enzyme-linked immunosorbent assays (ELISAs). PEs were prepared from single colonies of E. coli 
that were retained after panning on immobilized UV-inactivated Candid#1 virions. Wells of a 96-well plate were 
coated with 1.7 µg/µl of concentrated UV-inactivated Candid#1 virus that was diluted in carbonate/bicarbonate 
buffer overnight at 4 °C. Wells coated with the coating buffer alone were used as negative control. The wells were 
washed three times with PBS containing 0.1% Tween (PBST) and blocked with 1% casein in PBS for 1 h at room 
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temperature. After blocking, 100 µl of PE was added per well and incubated 1 h at room temperature. Wells were 
then washed with PBST and further incubated with a mouse anti-HA antibody followed by an anti-mouse anti-
body conjugated to HRP. After the addition of the HRP substrate, the optical density was measured at the wave-
length of 450 nm and a reference wavelength of 650 nm.
To determine binding of the purified VHHs to Candid#1 infected cells, Vero cells were seeded in 96-well 
plates at 20,000 cells per well and after overnight incubation at 37 °C were mock infected or infected with 50 PFU 
of Candid#1. Seventy two hours post infection (p.i.) cells were fixed with 2% paraformaldehyde (PFA) and then 
permeabilized with 0.15% Triton X-100 in PBS. After permeabilization the cells were blocked for 1 h at room 
temperature with 3% BSA 0.15% Tx-100 in PBS and incubated afterwards for 2 h with 1/10 serial dilution of the 
VHHs. Subsequently, the plates were incubated for 1 h at room temperature with a mouse anti-His antibody fol-
lowed by incubation with anti-mouse antibody conjugated to HRP. After the addition of the HRP substrate optical 
densities were determined in each well as described above.
VHH-ELISA was also performed by incubating infected or mock infected Vero cells with VHHs before fixa-
tion. In that case, the cells were first incubated with 1/10 serial dilutions of VHHs in Optimem® medium for 2 h 
in a 4% CO2 incubator at 37 °C. After incubation the cells were washed three times with PBS, fixed with 2% PFA 
and subsequently blocked and processed as mentioned above (without the permeabilization step).
Virus neutralization assays. Candid#1 virus (150 PFU) was mixed with 100 µl of PE that had been incu-
bated for 15 min at 65 °C to heat kill residual E. coli cells, and incubated at 37 °C during 1 h. Subsequently, the 
virus/PE mixture was added to 90% confluent Vero cells that had been seeded in 24 well plates. After 1 h incuba-
tion at 37 °C in a CO2 (5%) incubator, the inoculum was removed, cells were washed three times with medium 
and replenished with 0.5 ml of semisolid medium containing 0.7% methylcellulose in 0.5% FCS DMEM. At 7 days 
p.i. cells monolayers were fixed with 4% PFA and further stained with crystal violet to count the viral plaques.
To determine the virus neutralizing activity of the purified VHHs, Candid#1 (50 PFU) was mixed with 
1/10 serial dilutions of VHHs in Optimem® without serum and incubated at 37 °C during 1 h in a water bath. 
Subsequently the mix virus/VHH was added to 90% confluent Vero cells seeded in 96 well plates and incubated 
1 h in a 4% CO2 incubator at 37 °C. After infection, the cells were washed three times with medium and replen-
ished with fresh medium without serum. Seventy two h p.i. the cell monolayers were washed with PBS, fixed 
with 2% PFA and then permeabilized with 0.15% Triton X-100 in PBS. After permeabilization the wells were 
blocked for 1 h at room temperature with 3% milk in PBS and incubated afterwards with 1:2000 of a mix of 
N-mAbs and a mix of 1:2000 GPC-mAbs in PBS with 1.5% milk- 0.05% Tween. Finally, the wells were incubated 
1 h at room temperature with an anti-mouse antibody conjugated to HRP and viral plaques were visualized and 
counted after addition of TrueBlueTM peroxidase substrate. Alternatively ELISA peroxidase substrate was used 
to quantify the amount of viral antigen using an ELISA reader. GPC-mAbs mix was composed of 1:1:1 parts 
of GB03-BE08, QD04-AF03 and QC03-BF11 GPC-specific monoclonal antibodies (Biodefense and Emerging 
Infections Research Resources Repository (Bei resources)). N-specific mAbs mix was composed of 1:1:1 parts of 
SA02-BG12, QB06-AE05 and NA05-AG12 monoclonal antibodies (Bei resources)60.
Neutralization assays with purified VHHs were performed in Vero cells by conventional plaque assays, by the 
incubation of cell monolayers with semisolid medium for 7 days followed by fixation with 4% PFA and further 
visualization of viral plaques after crystal violet staining.
Immunofluorescence microscopy. Vero cells seeded in 96-well plates with glass bottoms were mock 
infected or infected with 50 PFU of Candid#1. Forty eight h p.i. cells were fixed with 2% PFA and then permeabi-
lized with 0.15% Triton X-100 in PBS. After permeabilization the wells were blocked for 1 h at room temperature 
with 3% BSA 0.15% Tx-100 in PBS and incubated afterwards 2 h with 10 µM of purified VHHs. Subsequently, 
cells were incubated 1 h at room temperature with a mouse anti-His antibody (1:2000, GE) followed by incuba-
tion with anti-mouse antibody conjugated to Alexa 488. Hoechst 1:1000 was added together with the secondary 
antibody. Monolayers were replenished with PBS and analyzed by confocal microscopy.
Immuno-fluorescence of non-fixed cells was performed by first incubating the cells with 10 µM of purified 
VHHs in Optimem® without phenol red indicator during 2 h in a 4% CO2 incubator at 37 °C. After incubation, 
the cells were washed three times with PBS, fixed with 2% PFA and subsequently blocked and processed as men-
tioned above (without permeabilization).
For double labeling (co-localization assays), monolayers were first incubated with 10 µM of VHHs during 
2 h and after washing were incubated during 1 h at RT with 1:600 dilution of the mAbs anti-GPC or anti-N. 
Afterwards monolayers were incubated with a rabbit anti-His antibody (1:600, Thermo Fisher) for 1 h at RT. After 
washes the conjugated antibodies goat anti-mouse Alexa 555 (1:600) and goat anti-rabbit Alexa 488 (1:600) were 
added in the presence of 1:1000 of Hoesch and incubated for 1 h at RT.
Colocalization in confocal images was calculated by statistical analysis with Volocity 6.3.1 software (Perkin 
Elmer, Coventry, UK). The Pearson’s correlation coefficient (P) was calculated using the Coste’s algorithm pro-
vided in the Volocity software package. Thirty to fifty cells positive for N- or GPC-specific mAbs were processed 
per setting.
Pre and post attachment, post-entry and pre-treatment assay. For the pre-attachment assay 50 
PFU of Candid#1 virus were mixed with 1/10 serial dilutions of VHHs in Optimem® without serum and incu-
bated for 1 h in a 37 °C. The mix was added to Vero cells seeded in 96 well plates and incubated 1 h at 37 °C. After 
infection, cells were washed three times with medium and replenished with fresh medium without serum. For 
the post-attachment assay 50 PFU of Candid#1 virus were added to pre-chilled Vero cells and incubated for 1 h 
at 4 °C. Cells were washed three times with cold medium to remove the unbound virus and incubated afterwards 
with 1/10 serial dilutions of VHHs during 1 h at 37 °C. After incubation the cells were washed three times with 
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medium and replenished with fresh medium without serum.. For the cell pre-treatment assay, Vero cells were 
incubated with 1/10 serial dilutions of VHHs 1 h at 37 °C, washed 3 times with cold medium and then chilled on 
ice for 15 min. Cells were then incubated with 50 PFU of Candid#1 virus 1 h at 4 °C and after washes with cold 
medium were shifted at 37 °C.
For all the conditions, the extent of viral replication was measured at 72 h p.i. by ELISA by using a mix of N- 
and GPC-specific mAbs as described above.
Syncytium formation assay. Vero cells seeded in 96 well plates were mock infected or infected with 
Candid#1 at an MOI of 0.05. At 48 h p.i. 1/10 serial dilutions of VHHs were added to the cells and incubated 
for 2 h at 37 °C. Cells were then washed with fresh medium and covered with DMEM pH 5.0 during 3 h in order 
to induce syncytium formation. Subsequently cells were replenished with DMEM pH 7.0 for 1 h and fixed with 
methanol for 10 min at −20 °C for Giemsa staining. After fixation cells were incubated with 0.4% Giemsa and 
examined for the presence of multinucleated cells by light microscopy. For IFA, GPC staining was performed as 
described above.
Generation of escape mutants. In vitro Candid#1 escape viruses were isolated by selection with VHHs. 
Vero cells were infected with serial dilutions of Candid#1 virus in the presence of 1000-fold the median inhib-
itory concentration of VHHs obtained from neutralization assay. Escape viruses were selected using standard 
techniques. After 3 passages in the presence of the VHHs, escape virus was amplified in Vero cells still in the 
presence of the respective VHHs. Total RNA was extracted from the supernatants and cDNA was synthetized 
using the arena primer (ARS1) as described elsewhere58. The PCR fragment corresponding to the nucleoprotein, 
glycoprotein precursor and Z protein were analyzed by sequencing after amplification using the following prim-
ers: N fw 5′-ATGGCACACTCCAAAGAGG-3′; N rv 5′-CAGTGCATAGGCTGCCTTCG-3′; GPC fw ATGG 
GGCAGTTCATTAGC-3′; GPC rv 5′-GATGTGTCCTCTTGCGCC-3′; Z fw ATGGGCAACTGCAACGG 
GGCATC-3′; Z rv 5′-TGGTGGTGGTGCTGTTGGCTCC-3′.
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